Trial Profile
A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms IMMUNED
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 10 Dec 2021 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 This trial has been completed in Austria, according to European Clinical Trials Database record. (2021-06-27)